Pregled bibliografske jedinice broj: 725553
Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second line therapy in patients with advanced (stage IIb and IV) non-small-cell lung cancer
Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second line therapy in patients with advanced (stage IIb and IV) non-small-cell lung cancer // ASCO
San Antonio (TX), Sjedinjene Američke Države, 2005. (poster, nije recenziran, sažetak, znanstveni)
CROSBI ID: 725553 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second line therapy in patients with advanced (stage IIb and IV) non-small-cell lung cancer
Autori
Čufer, T ; Vrdoljak, E ;
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Skup
ASCO
Mjesto i datum
San Antonio (TX), Sjedinjene Američke Države, 2005
Vrsta sudjelovanja
Poster
Vrsta recenzije
Nije recenziran
Ključne riječi
rak pluća
(lung cancer)
Sažetak
Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second line therapy in patients with advanced (stage IIb and IV) non-small-cell lung cancer
Izvorni jezik
Engleski
